This page is a list of EORTC clinical trials sponsored by the European Organisation for Research and Treatment of Cancer (EORTC).
Breast cancer
- EORTC 10085 – characterization of male breast cancer[1][2]
- EORTC 10863 – continuous tamoxifen versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate[3]
- EORTC 10951 – exemestane versus tamoxifen[4]
Older studies
- Nafoxidine versus ethinylestradiol[5]
- Levodopa versus nafoxidine[6]
Prostate cancer
The following prostate cancer trials have been conducted, among others:[7][8]
- EORTC 30761 – cyproterone acetate 250 mg/day versus medroxyprogesterone acetate 200 mg/day versus diethylstilbestrol 3 mg/day[7][9][10][11][12]
- EORTC 30762 – estramustine phosphate 280 mg/day (560 mg/day initially) versus diethylstilbestrol 3 mg/day[7][9][13][12]
- EORTC 30805 – orchiectomy versus orchiectomy plus cyproterone acetate (150 mg/day) versus low-dose diethylstilbestrol (1 mg/day)[14][15][16]
- EORTC 30843 – orchiectomy versus buserelin versus buserelin plus cyproterone acetate (150 mg/day)[7][17][18]
- EORTC 30853 – orchiectomy versus goserelin plus flutamide (750 mg/day)[7][19][20][21]
- EORTC 30892 – flutamide monotherapy (750 mg/day) versus cyproterone acetate (300 mg/day)[22][23][24]
- EORTC 30903 – prednisone versus flutamide[7]
- EORTC 30954 – intermittent combined androgen blockade (with GnRH agonist plus bicalutamide (50 mg/day))[7][25][26]
- EORTC 30958 – intermittent combined androgen blockade[27]
References
- ↑ Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, et al. (September 2017). "Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program". European Journal of Cancer. 82: 219–227. doi:10.1016/j.ejca.2017.01.034. PMID 28292559.
- ↑ Cardoso F, Bartlett JM, Slaets L, van Deurzen CH, van Leeuwen-Stok E, Porter P, et al. (February 2018). "Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program". Annals of Oncology. 29 (2): 405–417. doi:10.1093/annonc/mdx651. PMC 5834077. PMID 29092024.
- ↑ Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, et al. (December 2006). "Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)". European Journal of Cancer. 42 (18): 3178–3185. doi:10.1016/j.ejca.2006.08.020. PMID 17045796.
- ↑ Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. (February 2004). "The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'". Annals of Oncology. 15 (2): 211–217. doi:10.1093/annonc/mdh064. PMID 14760111.
- ↑ Heuson JC, Engelsman E, Blonk-Van Der Wijst J, Maass H, Drochmans A, Michel J, et al. (June 1975). "Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study". British Medical Journal. 2 (5973): 711–713. doi:10.1136/bmj.2.5973.711. PMC 1673940. PMID 1095121.
- ↑ Engelsman E, Heuson JC, Blonk Van Der Wijst J, Drochmans A, Maass H, Cheix F, et al. (June 1975). "Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study". British Medical Journal. 2 (5973): 714–715. doi:10.1136/bmj.2.5973.714. PMC 1673916. PMID 1095122.
- 1 2 3 4 5 6 7 Denis L (May 1998). "European Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996". Urology. 51 (5A Suppl): 50–57. doi:10.1016/s0090-4295(98)00076-4. PMID 9610558.
- ↑ Bollack C, Rougeron G (1988). "Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study". American Journal of Clinical Oncology. 11 (Suppl 2): S156–S159. doi:10.1097/00000421-198801102-00037. PMID 2977270. S2CID 20422041.
- 1 2 Pavone-Macaluso M, Lund F, Mulder JH, Smith PH, De Pauw M, Sylvester R (1980). "EORTC protocols in prostatic cancer. An interim report". Scandinavian Journal of Urology and Nephrology. 55 (Supplementum): 163–168. PMID 6938020.
- ↑ Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, et al. (1989). "EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European Organization for Research on Treatment of Cancer Urological Group". Progress in Clinical and Biological Research. 303: 111–116. PMID 2528735.
- ↑ Pavone-Macaluso M, Ingargiola GB, de Voogt H, Viggiano G, Barasolo E, Lardennois B, et al. (1987). "Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761". Progress in Clinical and Biological Research. 243A: 379–382. PMID 2958862.
- 1 2 de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S (February 1986). "Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762". The Journal of Urology. 135 (2): 303–307. doi:10.1016/s0022-5347(17)45620-5. PMID 2935644.
- ↑ Smith PH, Robinson M, Richards B, Suciu S, De Pauw M, Sylvester R, Denis L (June 1984). "Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762". Urology. 23 (6 Suppl): 64–68. doi:10.1016/s0090-4295(84)80101-6. PMID 6375083.
- ↑ Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R (1995). "The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate". European Urology. 28 (4): 273–283. doi:10.1159/000475067. PMID 8575493.
- ↑ Robinson MR (1988). "EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate". Progress in Clinical and Biological Research. 260: 101–110. PMID 2966402.
- ↑ Robinson MR (1987). "Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate". Progress in Clinical and Biological Research. 243A: 383–390. PMID 2958863.
- ↑ de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M (December 1990). "Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843". The Journal of Steroid Biochemistry and Molecular Biology. 37 (6): 965–969. doi:10.1016/0960-0760(90)90451-p. PMID 2149509. S2CID 13439306.
- ↑ de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R (1998). "Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group". European Urology. 33 (2): 152–158. doi:10.1159/000019547. PMID 9519356. S2CID 209144445.
- ↑ Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, et al. (1989). "Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group". Progress in Clinical and Biological Research. 303: 129–143. PMID 2528736.
- ↑ Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, et al. (September 1990). "Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group". Cancer. 66 (5 Suppl): 1045–1057. doi:10.1002/cncr.1990.66.s5.1045. PMID 2144206. S2CID 23659092.
- ↑ Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, et al. (1998). "Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center". European Urology. 33 (2): 144–151. doi:10.1159/000019546. PMID 9519355. S2CID 13056714.
- ↑ Schröder FH, Collette L, de Reijke TM, Whelan P (January 2000). "Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer". British Journal of Cancer. 82 (2): 283–290. doi:10.1054/bjoc.1999.0916. PMC 2363280. PMID 10646878.
- ↑ Collette L, de Reijke TM, Schröder FH (August 2003). "Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)". European Urology. 44 (2): 182–9, discussion 189. doi:10.1016/s0302-2838(03)00251-3. PMID 12875936.
- ↑ Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, et al. (April 2004). "Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892". European Urology. 45 (4): 457–464. doi:10.1016/j.eururo.2003.11.016. PMID 15041109.
- ↑ Kil PJ, Goldschmidt HM, Wieggers BJ, Kariakine OB, Studer UE, Whelan P, et al. (January 2003). "Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma". European Urology. 43 (1): 31–38. doi:10.1016/s0302-2838(02)00499-2. PMID 12507541.
- ↑ de Reijke TM (1997). "Intermittent androgen deprivation in advanced prostate cancer" (PDF). Urological Research. 25 (Suppl 2): S63–S66. doi:10.1007/BF00941990. PMID 9144889. S2CID 31327672.
- ↑ Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, et al. (November 2003). "Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study". European Urology. 44 (5): 505–511. doi:10.1016/s0302-2838(03)00375-0. PMID 14572746.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.